SCHEMBL5887237

SCHEMBL5887237

COc1cc(C2=CC=CC[CH]2)cc2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.37
ALDH1A1 P00352 4/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NQO1 P15559 1/20 0.37
PTGES O14684 2/20 0.36
ALOX5 P09917 2/20 0.36
HPGD P15428 4/20 0.36
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALOX15 P16050 1/20 0.35
ABCG2 Q9UNQ0 6/20 0.34
KDM4E B2RXH2 3/20 0.34
ABCB1 P08183 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8197756 0.77 NQO1 (0.54) MAPTALDH1A1NPSR1NQO1PTGES
SCHEMBL6047621 0.75 HSD17B1 (0.37) KDM4EMEN1KMT2A
SCHEMBL6047636 0.73 HPGD (0.43) MAPTALDH1A1NPSR1NQO1PTGES
SCHEMBL6047640 0.72 MAPT (0.36) MAPTALDH1A1NPSR1NQO1PTGES
SCHEMBL28802318 0.72 HPGD (0.54) MAPTALDH1A1NQO1PTGESALOX5
SCHEMBL5887354 0.69 SMN1; SMN2 (0.38) MAPTALDH1A1NPSR1HPGDLMNA
SCHEMBL13241087 0.68 PDGFRB (0.46) MAPTALDH1A1NQO1PTGESALOX5
SCHEMBL6047663 0.68 MAPT (0.35) MAPTALDH1A1NQO1PTGESALOX5
SCHEMBL19208975 0.67 NQO2 (0.50) MAPTALDH1A1NPSR1NQO1PTGES
SCHEMBL8986122 0.67 MAPT (0.52) MAPTALDH1A1NPSR1NQO1PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US claimed
EP-1418916-A1 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER Amgen Inc. (US) 2004-05-19 EP disclosed
WO-2003018022-A1 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AMGEN INC. (US) 2003-03-06 WO disclosed